BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25586952)

  • 1. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
    Yu W; Cai XW; Liu Q; Zhu ZF; Feng W; Zhang Q; Zhang YJ; Yao ZF; Fu XL
    Radiother Oncol; 2015 Feb; 114(2):195-200. PubMed ID: 25586952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
    Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
    Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma.
    Fan B; Fan P; Kong L; Sun X; Zhao S; Sun X; Fu Z; Zheng J; Ma L; Wang S; Hu M; Yu J
    Oncotarget; 2017 May; 8(21):34498-34506. PubMed ID: 28404900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation-Induced Esophagitis Masquerading as Disease Progression in Case of Esophageal Carcinoma: A Diagnostic Dilemma Solved on Follow-up FDG PET/CT.
    Mukherjee A; Chakraborty PS; Behera A; Bal C; Kumar R
    Clin Nucl Med; 2015 Jul; 40(7):e380-1. PubMed ID: 25706793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
    Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear correlation between patient survival and decreased percentage of tumor [(18)F]fluorodeoxyglucose uptake for late-course accelerated hyperfractionated radiotherapy for esophageal cancer.
    Ma JB; Song YP; Yu JM; Zhou W; Cheng EC; Zhang XQ
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1535-40. PubMed ID: 21705150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.
    Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J
    Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma.
    Zhang Y; Feng W; Gao LT; Cai XW; Liu Q; Zhu ZF; Fu XL; Yu W
    Radiother Oncol; 2021 Jun; 159():190-196. PubMed ID: 33812913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
    Yamashita H; Omori M; Takenaka R; Okuma K; Kobayashi R; Ohtomo K; Nakagawa K
    Radiother Oncol; 2014 Nov; 113(2):182-7. PubMed ID: 25466372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
    Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
    Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of nodal metastases on 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma are useful to guide treatment planning of radiotherapy.
    Liu CJ; Cheng JC; Lee JM; Cheng MF; Tzen KY; Yen RF
    Clin Nucl Med; 2015 May; 40(5):384-9. PubMed ID: 25674870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma].
    Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petenief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Hourry S; Talbot JN
    Cancer Radiother; 2005 May; 9(3):152-60. PubMed ID: 16023043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
    Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
    Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
    Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Houry S; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):340-5. PubMed ID: 16168829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.